Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?

    ... Erythropoiesis-stimulating agents (ESA) may reduce red blood cell transfusion requirements. MDS patients receiving ESA were reviewed for ...

    Research Article last updated 12/09/2015 - 8:52am.

  2. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies

    ... gene, which impairs the membrane expression on affected blood cells of a number of proteins, including the complement regulators CD55 ... leading to hemoglobin stabilization and transfusion independence in more than half of the patients. However, recent ...

    Research Article last updated 03/05/2013 - 9:38am.

  3. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies

    ... gene, which impairs the membrane expression on affected blood cells of a number of proteins, including the complement regulators CD55 ... leading to hemoglobin stabilization and transfusion independence in more than half of the patients. However, recent ...

    Research Article last updated 10/02/2012 - 9:57am.

  4. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

    ... to 20%. Oral and SC azacitidine decreased DNA methylation in blood, with maximum effect at day 15 of each cycle. Hematologic responses ... remission, hematologic improvement, or RBC or platelet transfusion independence) was 35% in previously treated patients and 73% in ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

    ... is approved for the treatment of patients who have transfusion-dependent anemia due to lower-risk MDS with chromosome 5q ... that lenalidomide is effective not only in reducing red blood cell (RBC) transfusion burden, but also in modifying the disease ...

    Research Article last updated 12/08/2015 - 1:06pm.

  6. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study

    ... with reduced overall survival were increasing age, transfusion dependency (defined as having received at least one red blood cell transfusion every 8 weeks over a period of 4 months), Eastern ...

    Research Article last updated 11/10/2015 - 10:47am.

  7. Blood Transfusion Safety and Risks

    ... Negative side effects of blood transfusion therapy are uncommon. Blood banks, hospitals, and health-care providers take many precautions to ...

    Page last updated 10/31/2014 - 2:36pm.

  8. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes

    ... Journal Title:  J Blood Med Primary Author:  ... del(5q) MDS, including reduction in red blood cell transfusion requirements and improvements in quality of life. Lenalidomide has ...

    Research Article last updated 03/02/2015 - 2:11pm.

  9. Jill Whitney – Since my diagnosis, my mission has been to fight back

    ... setbacks that kept me in isolation longer than expected. A blood infection (sepsis) sent me to the ICU for three days. I watched the days ... completed my 34th cycle of azacitidine and have not needed a transfusion in over 2 1/2 years. It has now been four years since my relapse, ...

    Patient Chronicle last updated 05/26/2015 - 9:29am.

  10. Myelodysplastic syndromes and the role of iron overload.

    ... in patients with MDS due to the long-term use of red blood cell transfusions in patients with symptomatic anemia . ... options for patients with MDS do not always reduce the transfusion burden, many patients will still need long-term transfusion ...

    Research Article last updated 10/11/2011 - 5:58pm.